** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket
** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial
** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX
** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body
** Co says the drug has been tested in over 140 patients and was well-tolerated
** As of last close, stock down 22.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。